Business Description
Joincare Pharmaceutical Group Industry Co Ltd
ISIN : US47973H2058
Share Class Description:
FRA:F9L: GDR - Reg SCompare
Compare
Traded in other countries / regions
600380.ChinaJCARE.SwitzerlandF9L.Germany IPO Date
2022-10-07Description
Joincare Pharmaceutical Group Industry Co Ltd is an integrated pharmaceutical company, the business scope covers healthcare products, APIs, final dosage forms, prescription drugs, OTCs, Chinese traditional medicine, chemical drugs, and testing agents. APIs are antibiotic series and their intermediates 7ACA, 4AA and F9. Prescription drugs focus on the realms of the digestive tract, a blood vessel of heart and brain, infection, tumor, nervous cerebrovascular section, urinary system etc. OTCs include gastrointestinal drug Dele-Livzon, Live Bifidobacterium Preparation, oral ulcer drugs Yiketie, cold medicine Antiviral Oral Granule, External use skin medicine.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.06 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.35 | |||||
| Debt-to-EBITDA | 1.37 | |||||
| Interest Coverage | 23.07 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 2.56 | |||||
| Beneish M-Score | -2.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.1 | |||||
| 3-Year EBITDA Growth Rate | 10.7 | |||||
| 3-Year EPS without NRI Growth Rate | 13.4 | |||||
| 3-Year FCF Growth Rate | 9.3 | |||||
| 3-Year Book Growth Rate | 9.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 13.21 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 7.76 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.12 | |||||
| Quick Ratio | 1.89 | |||||
| Cash Ratio | 1.38 | |||||
| Days Inventory | 162.17 | |||||
| Days Sales Outstanding | 64.97 | |||||
| Days Payable | 148.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Payout Ratio | 0.2 | |||||
| 3-Year Dividend Growth Rate | 4 | |||||
| 3-Year Average Share Buyback Ratio | 1.5 | |||||
| Shareholder Yield % | 2.68 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.59 | |||||
| Operating Margin % | 21.29 | |||||
| Net Margin % | 8.69 | |||||
| FCF Margin % | 20.34 | |||||
| ROE % | 10.19 | |||||
| ROA % | 3.87 | |||||
| ROIC % | 18.53 | |||||
| 3-Year ROIIC % | 10.27 | |||||
| ROC (Joel Greenblatt) % | 58.35 | |||||
| ROCE % | 13.83 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 15.89 | |||||
| Forward PE Ratio | 12.1 | |||||
| PE Ratio without NRI | 13.02 | |||||
| Shiller PE Ratio | 18.7 | |||||
| Price-to-Owner-Earnings | 39.3 | |||||
| PEG Ratio | 1.05 | |||||
| PS Ratio | 1.38 | |||||
| PB Ratio | 1.55 | |||||
| Price-to-Tangible-Book | 1.78 | |||||
| Price-to-Free-Cash-Flow | 6.82 | |||||
| Price-to-Operating-Cash-Flow | 5.08 | |||||
| EV-to-EBIT | 3.27 | |||||
| EV-to-EBITDA | 3.27 | |||||
| EV-to-Revenue | 0.74 | |||||
| EV-to-FCF | 3.63 | |||||
| Price-to-Projected-FCF | 0.6 | |||||
| Price-to-DCF (Earnings Based) | 0.4 | |||||
| Price-to-DCF (FCF Based) | 0.3 | |||||
| Price-to-Median-PS-Value | 0.9 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.06 | |||||
| Price-to-Graham-Number | 1.02 | |||||
| Price-to-Net-Current-Asset-Value | 15.62 | |||||
| Earnings Yield (Greenblatt) % | 30.58 | |||||
| FCF Yield % | 14.77 | |||||
| Forward Rate of Return (Yacktman) % | 21.74 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Joincare Pharmaceutical Group Industry Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2,071.028 | ||
| EPS (TTM) (€) | 0.956 | ||
| Beta | 0 | ||
| Volatility % | 1.81 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 12.6 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 12.6 - 12.6 | ||
| Shares Outstanding (Mil) | 187.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Joincare Pharmaceutical Group Industry Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Joincare Pharmaceutical Group Industry Co Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Joincare Pharmaceutical Group Industry Co Ltd Frequently Asked Questions
What is Joincare Pharmaceutical Group Industry Co Ltd(FRA:F9L)'s stock price today?
The current price of FRA:F9L is €12.60. The 52 week high of FRA:F9L is €12.60 and 52 week low is €12.60.
When is next earnings date of Joincare Pharmaceutical Group Industry Co Ltd(FRA:F9L)?
The next earnings date of Joincare Pharmaceutical Group Industry Co Ltd(FRA:F9L) is .
Does Joincare Pharmaceutical Group Industry Co Ltd(FRA:F9L) pay dividends? If so, how much?
Joincare Pharmaceutical Group Industry Co Ltd(FRA:F9L) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers